J David Lawson

7PUBLICATIONS
50CO-AUTHORS
Molecular targetsMedical biochemistry - proteins and peptides (incl. medical proteomics)Radiation and matterBiomolecular modelling and designGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos

|Mar 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.

John M Ketcham, Stephen J Harwood, Ruth Aranda

|Dec 29, 2023
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.

Christopher R Smith, Dan Chen, James G Christensen

|Aug 08, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.

Lars D Engstrom, Ruth Aranda, Laura Waters

|Dec 22, 2022
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.

Christopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad

|Oct 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor.

Jill Hallin, Vickie Bowcut, Andrew Calinisan

Pageof 2

Frequent Collaborators

6 joint publications

Matthew A Marx

5 joint publications

Christopher R Smith

4 joint publications

John M Ketcham

3 joint publications

Jill Hallin